Integra LifeSciences Holdings (IART)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 67,741 | 180,550 | 169,075 | 133,892 | 50,201 |
| Total stockholders’ equity | US$ in thousands | 1,587,880 | 1,804,400 | 1,684,800 | 1,514,870 | 1,416,740 |
| ROE | 4.27% | 10.01% | 10.04% | 8.84% | 3.54% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $67,741K ÷ $1,587,880K
= 4.27%
Integra Lifesciences Holdings Corp's return on equity (ROE) has exhibited fluctuations over the past five years. The ROE decreased to 4.27% in 2023 from 10.01% in 2022, marking a significant decline. Similarly, in 2021, the ROE was 10.04%, slightly higher than in 2022, before dropping to 8.84% in 2020. The lowest ROE of 3.54% was reported in 2019.
The downward trend in ROE in 2023 may indicate a decrease in the company's profitability relative to its equity compared to the previous year. Investors and stakeholders may need to further investigate the factors contributing to this decline to assess the company's financial performance and sustainable growth in the long term.
Peer comparison
Dec 31, 2023